Sign in

Private company

Decibel Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, one of the largest areas of unmet need in medicine. We have built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and our expertise in inner ear biology.”41 It is headquartered in Boston, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address1325 Boylston Street, Suite 500, Boston, Ma 022152
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34-$64.0M in 2022+62% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$39.6M-$39.6M20202021: -$50.2M-$50.2M2021+27%2022: -$64.0M-$64.0M2022+27%
Net income34-$63.0M in 2022+60% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$39.3M-$39.3M20202021: -$51.8M-$51.8M2021+32%2022: -$63.0M-$63.0M2022+22%
Fiscal year20192020202120222023
Research and development$25.3M3$29.8M4$40.3M4
Operating expenses$50.2M4$64.0M4
Operating income-$39.6M3-$50.2M4-$64.0M4
Income before tax-$50.0M4-$62.8M4
Income tax$03$1.8M4$240.0K4
Net income-$39.3M3-$51.8M4-$63.0M4
Earnings per share$14.843-$2.494-$2.524
Earnings per share (diluted)-$19.653-$2.494-$2.524
Shares (weighted, basic)21.7M shares425.0M shares4
Shares (weighted, diluted)21.7M shares425.0M shares4

Compare Decibel Therapeutics, Inc. with another company

Corporate structure

Decibel Therapeutics, Inc. is part of a group headed by Regeneron Pharmaceuticals. 30 entities, 14 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Decibel Therapeutics, Inc.

  • CITADEL ADVISORS LLC Filed SC 13G/A on Decibel Therapeutics, Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • BlackRock Filed SC 13G on Decibel Therapeutics, Inc., latest Feb 3, 2023
  • GV 2016, L.P. Filed SC 13G on Decibel Therapeutics, Inc., latest Feb 14, 2022
  • Third Rock Ventures III, L.P. Filed SC 13G on Decibel Therapeutics, Inc., latest Feb 14, 2022
  • Regeneron Pharmaceuticals Tarrytown, New York, United States
    • Decibel Therapeutics, Inc. Boston, Massachusetts
    • REGENERON INDIA PRIVATE LIMITED Subsidiary · 100% · Bangalore, India
    • Checkmate Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Eastside Campus Holdings LLC Subsidiary · New York, United States
    • Loop Road Holdings LLC Subsidiary · New York, United States
    • Old Saw Mill Holdings LLC Subsidiary · New York, United States
    • Oxular Acquisitions Limited Subsidiary · United Kingdom
    • Oxular Inc. Subsidiary · Delaware, United States
    • Regeneron Assurance, Inc. Subsidiary · New York, United States
    • Regeneron Austria GmbH Subsidiary · Austria
    • Regeneron Belgium SRL Subsidiary · Belgium
    • Regeneron Canada Company Subsidiary · Canada
    • Regeneron Clinical Genomics Laboratory LLC Subsidiary · Delaware, United States
    • Regeneron France SAS Subsidiary · France
    • Regeneron Genetics Center LLC Subsidiary · Delaware, United States
    • Regeneron GmbH Subsidiary · Germany
    • Regeneron Healthcare Solutions, Inc. Subsidiary · New York, United States
    • Regeneron International Holdings LLC Subsidiary · Delaware, United States
    • REGENERON IRELAND DESIGNATED ACTIVITY COMPANY Subsidiary · Dublin, Ireland
    • Regeneron Italy S.r.l. Subsidiary · Italy
    • Regeneron Japan KK Subsidiary · Japan
    • Regeneron NL B.V. Subsidiary · Netherlands
    • Regeneron Spain, S.L.U. Subsidiary · Spain
    • Regeneron Switzerland GmbH Subsidiary · Switzerland
    • Regeneron UK Limited Subsidiary · United Kingdom
    • and 4 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Decibel Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.7M4 Dec 31, 2022$11.6M4 Dec 31, 2021+0.9%
Accumulated depreciation$7.2M4 Dec 31, 2022$6.0M4 Dec 31, 2021+19.9%
Property and equipment, net$4.5M4 Dec 31, 2022$5.4M4 Jan 1, 2022−15.8%
Finance-lease assets$34.0K4 Dec 31, 2022$235.0K4 Jan 1, 2022−85.5%
Operating-lease assets (leased space)$9.9M4 Dec 31, 2022$11.5M4 Jan 1, 2022−14.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$34.6M4 Dec 31, 2022$36.5M4 Dec 31, 2021−5.1%
Marketable securities, current$70.0M4 Dec 31, 2022$112.3M4 Dec 31, 2021−37.7%
Marketable securities, non-current$13.5M4 Dec 31, 2021

Leadership

Who has led Decibel Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Laurence Reid2021

President

  1. Laurence Reid2021

Chief financial officer

  1. Elisabeth Leiderman2022
2025
Board members and other officers (16)

Timeline

  1. Sep 25, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights24
  2. Aug 25, 20238-K Other events25
  3. Aug 9, 20238-K Entered a material agreement; Other events26
  4. Jun 13, 20238-K Shareholder vote27
  5. Apr 6, 20238-K Bylaws or fiscal year changed28
  6. Mar 21, 20238-K Executive or director change29
  7. Mar 13, 20238-K Regulation FD disclosure30
  8. Jan 9, 20238-K Regulation FD disclosure31
  9. Oct 17, 20228-K Other events32
  10. Oct 12, 20228-K Executive or director change33
  11. Sep 20, 20228-K Other events34
  12. Sep 13, 20228-K Executive or director change35
  13. Sep 17, 2021New chief executive Laurence Reid becomes CEO7

Filings

95 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 16 major events, 38 insider forms, 9 large holders, 24 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Oct 10, 202315-12G EDGAR
  3. Oct 6, 2023EFFECT EDGAR
  4. Sep 27, 2023SC 13D/A EDGAR
  5. Sep 25, 2023S-8 POS EDGAR
  6. Sep 25, 2023S-8 POS EDGAR
  7. Sep 25, 2023S-8 POS EDGAR
  8. Sep 25, 2023POS AM EDGAR
  9. Sep 25, 20238-K EDGAR
  10. Sep 25, 2023SC 14D9/A EDGAR
  11. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  12. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  13. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  14. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  15. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  16. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  17. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  18. Sep 25, 20234 FORM 4 SUBMISSION EDGAR
  19. Sep 12, 2023SC 14D9/A EDGAR
  20. Sep 8, 2023SC 14D9/A EDGAR

The 95 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 0 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 3, 2022Trask AnnaChief People OfficerSale378$5.03$1.9KForm 4
Dec 2, 2021Trask AnnaChief People OfficerSale5,291$6.37$33.7KForm 4
Nov 3, 2021Trask AnnaChief People OfficerSale378$8.34$3.2KForm 4
Nov 2, 2021Trask AnnaChief People OfficerSale4,913$8.31$40.8KForm 4
Oct 14, 2021Trask AnnaChief People OfficerSale5,364$7.55$40.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Decibel Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDecibel Therapeutics, Inc.1
  • CIK0001656536
  • Employer ID (EIN)46-41987091
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1325 Boylston Street, Suite 500, Boston, MA 022151
  • Phone617-370-87011
  • Shares outstanding25,126,935 as of Aug 1, 20236
  • Public float$70.8M as of Jun 30, 20224
  • On EDGAR sinceOct 27, 20151
  • Filings177 in all: 4 (52), 3 (27), 8-K (21), 10-Q (8), CORRESP (5), SC 13G (5), 10-K (3), EFFECT (3)1
    All 42 form types

    S-1/A (3), S-8 (3), S-8 POS (3), SC 13G/A (3), SC 14D9/A (3), SC TO-T/A (3), UPLOAD (3), D (2), DEF 14A (2), DEFA14A (2), SC 13D (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), D/A (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), PRE 14A (1), S-1 (1), S-1MEF (1), S-3 (1), SC 13D/A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 14, 2023
    Quarterly report (10-Q) Aug 11, 2023
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Sep 25, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41